Lack of Associations between XPC Gene Polymorphisms and Neuroblastoma Susceptibility in a Chinese Population

Table 1

Genotype and allele frequencies of the three selected polymorphisms and neuroblastoma susceptibility in a Chinese population.

Genotype	Cases ()	Controls ()		Crude OR (95% CI)		Adjusted OR (95% CI)
rs2228001 (HWE = 0.948)
AA	99 (39.13)	218 (41.05)		1.00		1.00
AC	118 (46.64)	245 (46.14)		1.06 (0.77–1.47)	0.722	1.05 (0.76–1.45)	0.769
CC	36 (14.23)	68 (12.81)		1.17 (0.73–1.86)	0.521	1.15 (0.72–1.84)	0.555
Additive			0.807	1.08 (0.86–1.34)	0.520	1.07 (0.86–1.33)	0.563
Dominant	154 (60.87)	313 (58.95)	0.608	1.08 (0.80–1.47)	0.608	1.07 (0.79–1.46)	0.656
Recessive	217 (85.77)	463 (87.19)	0.583	1.13 (0.73–1.75)	0.583	1.12 (0.73–1.74)	0.604
rs2228000 (HWE = 0.988)
CC	111 (43.87)	205 (38.61)		1.00		1.00
CT	108 (42.69)	250 (47.08)		0.80 (0.58–1.10)	0.170	0.80 (0.58–1.10)	0.166
TT	34 (13.44)	76 (14.31)		0.83 (0.52–1.32)	0.422	0.84 (0.52–1.33)	0.453
Additive			0.368	0.88 (0.71–1.09)	0.244	0.88 (0.71–1.10)	0.257
Dominant	142 (56.13)	326 (61.39)	0.160	0.80 (0.59–1.09)	0.160	0.81 (0.59–1.09)	0.162
Recessive	219 (86.56)	455 (85.69)	0.742	0.93 (0.60–1.44)	0.742	0.94 (0.61–1.46)	0.785
rs2229090 (HWE = 0.994)
GG	99 (39.13)	191 (35.97)		1.00		1.00
GC	105 (41.50)	255 (48.02)		0.79 (0.57–1.11)	0.175	0.79 (0.57–1.10)	0.169
CC	49 (19.37)	85 (16.01)		1.11 (0.73–1.71)	0.626	1.11 (0.73–1.71)	0.622
Additive			0.204	1.00 (0.81–1.24)	0.971	1.00 (0.81–1.24)	0.972
Dominant	154 (60.87)	340 (64.03)	0.392	0.87 (0.64–1.19)	0.392	0.87 (0.64–1.19)	0.384
Recessive	204 (80.63)	446 (83.99)	0.243	1.26 (0.85–1.86)	0.243	1.26 (0.86–1.87)	0.237

test for genotype distributions between neuroblastoma cases and cancer-free controls.
Adjusted for age and gender.